240 related articles for article (PubMed ID: 19014204)
1. Single technology appraisals by NICE: are they delivering faster guidance to the NHS?
Barham L
Pharmacoeconomics; 2008; 26(12):1037-43. PubMed ID: 19014204
[TBL] [Abstract][Full Text] [Related]
2. How long has NICE taken to produce Technology Appraisal guidance? A retrospective study to estimate predictors of time to guidance.
Casson SG; Ruiz FJ; Miners A
BMJ Open; 2013 Jan; 3(1):. PubMed ID: 23315516
[TBL] [Abstract][Full Text] [Related]
3. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
Kaltenthaler E; Papaioannou D; Boland A; Dickson R
Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
[TBL] [Abstract][Full Text] [Related]
4. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
[TBL] [Abstract][Full Text] [Related]
5. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
6. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
7. Differences in cancer drug assessment between Spain and the United Kingdom.
Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
[TBL] [Abstract][Full Text] [Related]
8. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
[TBL] [Abstract][Full Text] [Related]
9. NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium.
Ford JA; Waugh N; Sharma P; Sculpher M; Walker A
BMJ Open; 2012; 2(1):e000671. PubMed ID: 22290398
[TBL] [Abstract][Full Text] [Related]
10. Report blames NICE for hastening decline of UK biotech.
Moran N
Nat Biotechnol; 2009 Mar; 27(3):215-7. PubMed ID: 19270658
[No Abstract] [Full Text] [Related]
11. Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.
Rose M; Rice S; Craig D
Pharmacoecon Open; 2018 Jun; 2(2):97-107. PubMed ID: 29623616
[TBL] [Abstract][Full Text] [Related]
12. The impact of rarity in NICE's health technology appraisals.
Clarke S; Ellis M; Brownrigg J
Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
[TBL] [Abstract][Full Text] [Related]
13. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
14. The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process.
Carroll C; Kaltenthaler E; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Value Health; 2017 Jun; 20(6):785-791. PubMed ID: 28577696
[TBL] [Abstract][Full Text] [Related]
15. Medicine characteristics affecting the time to guidance publication by National Institute for Health and Care Excellence in the single technology appraisal process.
Takada S; Narukawa M
Int J Technol Assess Health Care; 2021 Dec; 38(1):e11. PubMed ID: 34933699
[TBL] [Abstract][Full Text] [Related]
16. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE).
Buxton M
Value Health; 2001; 4(3):212-6. PubMed ID: 11705183
[TBL] [Abstract][Full Text] [Related]
17. Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer.
Connock M; Hyde C; Moore D
Pharmacoeconomics; 2011 Oct; 29(10):827-37. PubMed ID: 21770482
[TBL] [Abstract][Full Text] [Related]
18. Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer.
Kaltenthaler E; Tappenden P; Booth A; Akehurst R
Health Policy; 2008 Sep; 87(3):389-400. PubMed ID: 18387689
[TBL] [Abstract][Full Text] [Related]
19. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
[TBL] [Abstract][Full Text] [Related]
20. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
